Crosslinked layered surfaces of heparin and poly(L-lysine) enhance mesenchymal stromal cells behavior in the presence of soluble interferon gamma
Crosslinked layered surfaces of heparin and poly(L-lysine) enhance mesenchymal stromal cells behavior in the presence of soluble interferon gamma
复制标题
肝素和聚(L-赖氨酸)的交联层状表面在可溶性干扰素γ存在下增强间充质基质细胞的行为
DOI:
10.1159/000521609
复制
发表时间:
2021
影响因子:
2.7
通讯作者:
Almodovar, Jorge
中科院分区:
文献类型:
--
作者:
Haseli, Mahsa;Pinzon-Herrera, Luis;Almodovar, Jorge
Human mesenchymal stromal cells (hMSCs) are multipotent cells that have been proposed for the treatment of immune-mediated diseases. Culturing hMSCs on tissue culture plastic reduces their therapeutic potential in part due to the lack of extracellular matrix components. The aim of this study is to evaluate multilayers of heparin and poly (L-lysine)(HEP/PLL) as a bioactive surface for hMSCs stimulated with soluble interferon gamma (IFN-γ). Multilayers were formed, via layer-by-layer assembly, with HEP as the final layer and supplemented with IFN-γ in the culture medium. Multilayer construction and chemistry were confirmed using Azure A staining, quartz crystal microbalance, and X-ray photoelectron spectroscopy. hMSCs adhesion, viability, and differentiation, were assessed. Results showed that (HEP/PLL) multilayer coatings were poorly adhesive for hMSCs. However, performing chemical crosslinking using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide significantly enhanced hMSCs adhesion and viability. The immunosuppressive properties of hMSCs cultured on crosslinked (HEP/PLL) multilayers were confirmed by measuring indoleamine 2, 3-dioxygenase activity. Lastly, hMSCs cultured on crosslinked (HEP/PLL) multilayers in the presence of soluble IFN-γ successfully differentiated towards the osteogenic and adipogenic lineages as confirmed by Alizarin red, and oil-red O staining, as well as alkaline phosphatase activity. This study suggests that crosslinked (HEP/PLL) films can modulate hMSCs response to soluble factors, which may improve hMSCs-based therapies aimed at treating several immune diseases.